Dual blockade strategies of immune checkpoint inhibitors and CXCR4 inhibitors will condition the tumour microenvironment, re-increase T cell infiltration, and improve therapeutic outcomes from immunotherapy (Table 3) [101]. Here, CXCR4 is linked to neoplasm.